These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291 [TBL] [Abstract][Full Text] [Related]
10. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872 [TBL] [Abstract][Full Text] [Related]
12. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels. Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632 [TBL] [Abstract][Full Text] [Related]
13. The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: a potential therapeutic opportunity for atherosclerotic thrombosis. Jiang P; Xue D; Zhang Y; Ye L; Liu Y; Makale M; Kesari S; Edgington TS; Liu C Thromb Res; 2014 Apr; 133(4):657-66. PubMed ID: 24485401 [TBL] [Abstract][Full Text] [Related]
14. Blood-borne tissue factor activity predicts major cerebrovascular events in patients undergoing carotid endarterectomy: results from a 1-year follow-up study. Krupinski J; Turu MM; Font MA; Catena E; Slevin M; Morchon S; Rubio F; Badimon L; Martínez-González J Cerebrovasc Dis; 2008; 25(1-2):32-9. PubMed ID: 18033956 [TBL] [Abstract][Full Text] [Related]
15. Low thrombogenicity of calcified atherosclerotic plaques is associated with bone morphogenetic protein-2-dependent inhibition of tissue factor expression. Egorina EM; Sovershaev MA; Bogdanov VY; Sovershaev TA; Fallon JT; Seredkina N; Østerud B; Hansen JB Blood Coagul Fibrinolysis; 2011 Dec; 22(8):642-50. PubMed ID: 21897206 [TBL] [Abstract][Full Text] [Related]
16. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Crawley J; Lupu F; Westmuckett AD; Severs NJ; Kakkar VV; Lupu C Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1362-73. PubMed ID: 10807755 [TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein -7 increases thrombogenicity of lipid-rich atherosclerotic plaques via activation of tissue factor. Sovershaev MA; Egorina EM; Bogdanov VY; Seredkina N; Fallon JT; Valkov AY; Østerud B; Hansen JB Thromb Res; 2010 Oct; 126(4):306-10. PubMed ID: 20656331 [TBL] [Abstract][Full Text] [Related]
18. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Golledge J; Mangan S; Clancy P Stroke; 2007 May; 38(5):1501-8. PubMed ID: 17363721 [TBL] [Abstract][Full Text] [Related]
19. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Hutter R; Valdiviezo C; Sauter BV; Savontaus M; Chereshnev I; Carrick FE; Bauriedel G; Lüderitz B; Fallon JT; Fuster V; Badimon JJ Circulation; 2004 Apr; 109(16):2001-8. PubMed ID: 15078795 [TBL] [Abstract][Full Text] [Related]
20. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]